Exact Sciences Corp
EXAS: XNAS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$15.00 | Wth | Jcydjrtm |
As Liquid Biopsy Competition Looms, Exact's Growth Stays Strong; Shares Undervalued
Exact Sciences had a good start to the year, and first-quarter sales of $487 million was slightly above FactSet consensus and in line with our forecasts. We maintain our no-moat, positive moat trend rating, and $76 fair value estimate. After a decline of over 6% on April 26 (seemingly related to broad-based market declines), we now see shares as undervalued, closing at a 23% discount to what we think they are worth.